Skip to content

Virtual Reality for Anxiety Relief in Infertile Women

The Effect of Virtual Reality Application on Anxiety Before and After Embryo Transfer in Infertile Women

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07020975
Enrollment
80
Registered
2025-06-13
Start date
2025-03-01
Completion date
2026-03-01
Last updated
2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Assisted Reproductive Treatments, Embryo Transfer, Infertility, Stress, Virtual Goggles, VR, Women

Keywords

Anxiety, Assisted Reproductive Treatments, Women, Nurse, VR, Technology, Infertility, Embryo Transfer

Brief summary

This study examines the impact of virtual reality (VR) applications on anxiety levels before and after embryo transfer procedures. The clinical trial will involve 80 participants, aged 18 to 50, who are receiving treatment at a healthcare facility in the Turkish Republic of Northern Cyprus (TRNC). The primary objective is to evaluate the effectiveness of VR as an intervention for reducing anxiety in individuals undergoing assisted reproductive treatments.

Detailed description

This doctoral study aims to evaluate the use of virtual reality (VR) as an innovative, non-invasive intervention for managing anxiety during embryo transfer in assisted reproductive technology (ART). A randomized clinical trial will be conducted with 80 participants, aged 18 to 50, undergoing fertility treatment at a healthcare facility in the Turkish Republic of Northern Cyprus (TRNC). Participants will be randomly assigned to one of two groups: the intervention group (n=40), which will experience a VR session both before and after the embryo transfer, and the control group (n=40), which will receive standard care without VR. Anxiety levels will be assessed using the State-Trait Anxiety Inventory (STAI) at two time points-pre- and post-embryo transfer. The primary objective of this study is to determine the effectiveness of VR in reducing procedural anxiety, a factor known to negatively affect patient experience and potentially influence treatment outcomes. The findings are expected to support the integration of patient-centered, technology-enhanced strategies in reproductive healthcare practices.

Interventions

VR Glasses is used to help people be in a virtual reality other than their real life. What we use this for; to get away infertile women from her stressfull environment to another virtual reality before their embryo transfer.

Sponsors

Cyprus Aydin University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Volunteered to participate in the research, * 18-50 years old * No vision and hearing problems, * Not disoriented in time and place, * Primary infertile * Not having communication problem * Can read & write * No mental pathological disease

Exclusion criteria

* Secondary infertility * Having experienced bleeding, miscarriage, etc. after embryo transfer, * Difficulty communicating, * Problems such as migraine, vertigo, dizziness, * Patients who wear prescription glasses and have vision problems without glasses * Refused to participate in the research * Patients with psychiatric pathology

Design outcomes

Primary

MeasureTime frameDescription
Anxiety level of the women who went through embryo transfer.1 yearThis study aims to assess the anxiety levels of women who undergo a virtual reality (VR) experience before and after embryo transfer. The participants will be divided into two groups: those who receive relaxing Zen music and view natural landscapes through VR glasses, and those who do not. Anxiety levels will be objectively measured using the State-Trait Anxiety Inventory, both before and after the embryo transfer procedure.

Countries

Cyprus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026